Global Cancer Technology Inc CEO John Clark tells Proactive the privately-held biopharmaceutical company will look to raise $9M through a Regulation A+ offering, where the group will offer up to 3,500,000 shares of its common stock at $2.00 per share.
Clark says the San Diego, California-based group intends to use a portion of its net proceeds to develop and commercialize its recently licensed technology to treat the coronavirus using nanoparticles, UV light and chest x-rays.